Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients
Kevin Prigent, Charline Lasnon, Emilien Ezine, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 8, pp. 2573-2585
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
Egesta Lopci, Rodney J. Hicks, Antonia Dimitrakopoulou-Strauß, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 7, pp. 2323-2341
Open Access | Times Cited: 79
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers
Virginia Liberini, Riccardo Laudicella, Martina Capozza, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2201-2201
Open Access | Times Cited: 37
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy
Romain-David Seban, Jean‐Baptiste Assié, Étienne Giroux-Leprieur, et al.
Lung Cancer (2021) Vol. 159, pp. 45-55
Open Access | Times Cited: 33
Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
Egesta Lopci
Journal of Clinical Medicine (2021) Vol. 10, Iss. 21, pp. 5160-5160
Open Access | Times Cited: 28
PET/CT variants and pitfalls in malignant melanoma
Nicolas Aide, Amir Iravani, Kevin Prigent, et al.
Cancer Imaging (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer
Romain-David Seban, Roman Rouzier, Aurélien Latouche, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 11, pp. 3560-3570
Closed Access | Times Cited: 25
Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons
William Karlsen, Lin Akily, M. Mierzejewska, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1990-1990
Open Access | Times Cited: 3
Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy
Xiaoqing Xing, Qing Zhao, Jinyun Zhou, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 6, pp. 1671-1688
Open Access | Times Cited: 8
Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study
Christos Sachpekidis, Annette Kopp‐Schneider, Jessica C. Hassel, et al.
EJNMMI Research (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
Laëtitia Vercellino, Dorine de Jong, Laurent Dercle, et al.
Diagnostics (2022) Vol. 12, Iss. 5, pp. 1116-1116
Open Access | Times Cited: 14
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
Adrien Holzgreve, Julian Taugner, Lukas Käsmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 8, pp. 2466-2476
Open Access | Times Cited: 6
The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
Christos Sachpekidis, Vivienn Weru, Annette Kopp‐Schneider, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 9, pp. 2699-2714
Open Access | Times Cited: 6
The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors
Jelena Levi, Hong Song
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 5
Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
Christos Sachpekidis, Christoph K. Stein‐Thoeringer, Annette Kopp‐Schneider, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 12, pp. 3709-3722
Open Access | Times Cited: 5
Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging
Christos Sachpekidis, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauß
The Quarterly Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 66, Iss. 3
Closed Access | Times Cited: 9
Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach
Antonia Dimitrakopoulou-Strauß, Christos Sachpekidis, Jessica C. Hassel, et al.
Cancer Biotherapy and Radiopharmaceuticals (2023) Vol. 38, Iss. 4, pp. 225-231
Closed Access | Times Cited: 4
Preoperative Body Composition Combined with Tumor Metabolism Analysis by PET/CT Is Associated with Disease-Free Survival in Patients with NSCLC
Hongpei Tan, Mengtian Ma, Jing Huang, et al.
Contrast Media & Molecular Imaging (2022) Vol. 2022, Iss. 1
Open Access | Times Cited: 7
[18F]FDG PET/CT Integration in Evaluating Immunotherapy for Lung Cancer: A Clinician’s Practical Approach
Juliette Brezun, Nicolas Aide, Evelyne Péroux, et al.
Diagnostics (2024) Vol. 14, Iss. 18, pp. 2104-2104
Open Access | Times Cited: 1
Spleen Glucose Metabolism on [18F]-FDG PET/CT for Cancer Drug Discovery and Development cannot be Overlooked
Romain-David Seban, Shwe Synn, Izza Muneer, et al.
Current Cancer Drug Targets (2021) Vol. 21, Iss. 11, pp. 944-952
Closed Access | Times Cited: 8
PET/CT in Inflammatory and Auto-immune Disorders: Focus on Several Key Molecular Concepts, FDG, and Radiolabeled Probe Perspectives
Florent L. Besson, Gaëtane Nocturne, Nicolas Noël, et al.
Seminars in Nuclear Medicine (2023) Vol. 54, Iss. 3, pp. 379-393
Open Access | Times Cited: 3
Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
Guillaume Manson, Amaeshi Chukwunonye Lemchukwu, Fatima-Zohra Mokrane, et al.
European Radiology (2022) Vol. 32, Iss. 9, pp. 6536-6544
Closed Access | Times Cited: 5
Comparing [18F]FDG PET/CT response criteria in melanoma and lung cancer patients treated with immunotherapy: a systematic review
Hanna Saadani, Else A. Aalbersberg, Winnie Schats, et al.
Clinical and Translational Imaging (2022) Vol. 10, Iss. 6, pp. 643-661
Closed Access | Times Cited: 5
Clinical Value of 18F-FDG PET/CT Scan and Cytokine Profiles in Secondary Hemophagocytic Lymphohistiocytosis in Idiopathic Inflammatory Myopathy Patients: A Pilot Study
Junyu Liang, Heng Cao, Bowen Wu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 7
Does high [18F]FDG uptake always mean poor prognosis? Colon cancer with high-level microsatellite instability is associated with high [18F]FDG uptake on PET/CT
Jongtae Cha, Honsoul Kim, Hye Jung Shin, et al.
European Radiology (2023) Vol. 33, Iss. 11, pp. 7450-7460
Closed Access | Times Cited: 2
Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy
Evelien A. J. van Genugten, Jetty A.M. Weijers, Sandra Heskamp, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top